About Hizentra

Hizentra is the first and only 20% Sub-Q Ig (subcutaneous immunoglobulin) therapy approved by the FDA for people living with primary immunodeficiency disease, or PIDD.

Overview of Hizentra
Hizentra is the Sub-Q therapy that fits your life. See how Hizentra provides freedom and flexibility while treating PIDD.

Benefits of Hizentra
Find out about short infusion times, the safety of Hizentra, and the manufacturing process.

Self-Administration
Hizentra is a therapy for PIDD that you can administer yourself. Watch a video to learn how, see what supplies you need, and learn how to get expert help.

What to Expect
Injection-site reactions are one of the most common types of adverse reactions to Hizentra, but they are typically mild to moderate. Site reactions may include symptoms of redness, swelling, itching, heat, and pain. Other common reactions reported in the clinical trial were headache, vomiting, pain, and fatigue.

Questions About Hizentra
Questions about Hizentra? Find answers about treatment with Hizentra, reimbursement, and assistance programs.

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra^®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Hizentra should not be used if you have had serious negative reactions to immune globulin (Ig) preparations or a deficiency of an Ig known as IgA. Because Hizentra contains the amino acid proline as stabilizer, patients with hyperprolinemia (too much proline in the blood) should not take Hizentra.

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Your doctor will monitor for potentially serious reactions that have been seen with Ig treatment, including thrombotic events (blood clotting); aseptic meningitis syndrome (brain swelling); osmotic nephropathy (a kidney condition); hemolysis (a blood problem) and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were injection-site reactions (swelling, pain, redness, heat or itching); headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Vaccines (such as measles, mumps and rubella) might not work as well if you are using Hizentra. Before receiving a vaccination, tell the healthcare professional that you are being treated with Hizentra. Also tell your doctor if you are pregnant or nursing, or if you plan to become pregnant.

You are encouraged to report negative effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.